Telomir Pharmaceuticals is aiming to develop a breakthrough in human longevity science through a new drug. And they’re seeing compelling validation that it might work from an initial test in dogs.
What’s happening:
- Telomir Pharmaceuticals (NASDAQ: TELO) has been making potential breakthroughs in developing new therapeutics for human longevity through the pre-clinical advancement of their novel drug Telomir-1
The big idea:
- Telomeres are a region of repetitive DNA sequences at the end of a chromosome and ultimately protect the ends of chromosomes from becoming damaged or frayed
- Telomeres are particularly important during cell division as they allow cells to divide without losing genes
- However, telomeres tend to shorten as human beings age which reduces their ability to protect chromosomes and can ultimately increase the likelihood of age related and degenerative diseases forming
- Telomir Pharmaceuticals novel therapeutic Telomir-1 is aiming to elongate telomeres, sustain self renewal of stem cells and prevent against telomeres shortening as human beings age
Why it matters:
- Telomir Pharmaceuticals previously saw potential breakthrough validation for Telomir-1 when dosing two different dogs who both had preexisting health challenges, with one dog showing remission from terminal cancer and the other dog regaining full mobility after suffering from severe arthritis
Going deeper:
- Telomir Pharmaceuticals is specifically targeting age related inflammatory diseases such as osteoarthritis which currently has no effective singular treatment and instead relies on mitigating pain through different medications, therapy and even surgeries
- Through a collaboration with Italian life sciences company InSilicoTrials, Telomir-1 was previously run through advanced modelling and simulations made possible by artificial intelligence technology to determine that the mechanism of action may be a potent metal inhibitor which could potentially lead to reversing aging through the regeneration of telomeres
The intrigue:
- The Nobel Assembly at the prestigious Swedish university Karolinska Institute previously awarded the Nobel Prize in Physiology or Medicine to a team of scientific researchers for the discovery of how chromosomes are protected by telomeres